Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) EBT (2016 - 2025)

Ocular Therapeutix has reported EBT over the past 13 years, most recently at -$65.2 million for Q4 2025.

  • Quarterly results put EBT at -$65.2 million for Q4 2025, down 33.13% from a year ago — trailing twelve months through Dec 2025 was -$263.5 million (down 59.62% YoY), and the annual figure for FY2025 was -$263.5 million, down 59.62%.
  • EBT for Q4 2025 was -$65.2 million at Ocular Therapeutix, up from -$68.0 million in the prior quarter.
  • Over the last five years, EBT for OCUL hit a ceiling of -$19.5 million in Q1 2022 and a floor of -$68.0 million in Q3 2025.
  • Median EBT over the past 5 years was -$22.9 million (2022), compared with a mean of -$34.4 million.
  • Biggest five-year swings in EBT: rose 10.95% in 2022 and later tumbled 115.51% in 2024.
  • Ocular Therapeutix's EBT stood at -$19.7 million in 2021, then dropped by 5.38% to -$20.8 million in 2022, then dropped by 9.42% to -$22.7 million in 2023, then tumbled by 115.51% to -$49.0 million in 2024, then crashed by 33.13% to -$65.2 million in 2025.
  • The last three reported values for EBT were -$65.2 million (Q4 2025), -$68.0 million (Q3 2025), and -$67.2 million (Q2 2025) per Business Quant data.